Eleven Biotherapeutics reports $33.5 million net loss in 2015

Eleven Biotherapeutics reported a net loss applicable to common stockholders of $33.5 million, or $1.76 per share, in 2015 compared with $34.7 million, or $2.37 per share, in 2014, according to a company press release. Research and development expenses were reported at $26.3 million in 2015 compared with $26.7 million in 2014. Research and development expenses increased from $5.3 million in the fourth quarter of 2014 to $8.1 million for the same quarter in 2015, partly attributable to expenses related to development of EBI-031, the company’s preclinical product candidate for treatment of diabetic macular edema and uveitis, offset by decreased expenses related to development of EBI-005 (isunakinra), which the company is no longer pursuing as a treatment for allergic conjunctivitis, according to the release.

Publication Exclusive: Intraoperative OCT benefits anterior segment surgeries

With FDA clearance of three intraoperative OCT systems over the past 2 years, the technology is rapidly moving from potential to practice.These microscope-integrated systems — the En-Focus intrasurgical OCT system (Bioptigen, a division of Leica Microsystems), the Rescan 700 (Carl Zeiss Meditec) and the iOCT (Haag-Streit) — allow for real-time, high-quality imaging that can influence surgical decision-making and potentially contribute to achieving better outcomes in anterior segment surgery.